Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 87 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 87 versus QOLIANA.
FENTANYL-87 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing cAMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3–12 hours (mean 7 hours) in adults; prolonged to up to 20–30 hours in elderly, critically ill, or patients with hepatic impairment. Context-sensitive half-life increases with infusion duration.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Primarily hepatic metabolism (>90%) to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for approximately 75% of total elimination, with about 9% excreted unchanged in urine. Fecal excretion is minimal (<9%).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist